Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

doi:10.3748/wjg.v25.i1.118

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8557)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-11) series.

Item

Count

PDF

572

WORD

260

HTML

4304

Figures (1-8)

373

Tables (1-11)

325

Sum=5834

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

923

Download

1800

Sum=2723

Jan 7, 2019 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jan 7, 2019; 25(1): 118-137
Published online Jan 7, 2019. doi: 10.3748/wjg.v25.i1.118

Table 1 Predictive factors for complete pathological response in univariate logistic regression analysis for all patients

Variable		Non-pCR (n = 331) n P₅₀ (P₂₅-P₇₅)	pCR (n = 72) n P₅₀ (P₂₅-P₇₅)	pCR rate	P-value
Gender	Male	232	49	17.44%	0.653
Gender	Female	96	23	19.33%	0.653
Age (yr)	≤ 60	210	54	20.45%	0.07
Age (yr)	> 60	119	18	13.14%	0.07
BMI (kg/cm²)	< 25	231	53	18.66%	0.581
BMI (kg/cm²)	≥ 25	78	15	16.13%	0.581
Hemoglobin (g/L)	≤ 125	109	16	12.80%	0.126
Hemoglobin (g/L)	> 125	172	41	19.25%	0.126
NLR	> 3	37	11	22.92%	0.227
NLR	≤ 3	244	46	15.86%	0.227
Platelet (× 10⁹/L)		237.5 (200.25-286.75)	246 (200.5-268.5)		0.981
ApoA1 (g/L)		1.29 (1.13-1.44)	1.3 (1.15-1.52)		0.454
ApoB (g/L)		0.98 (0.79-1.14)	0.97 (0.82-1.19)		0.382
The interval (d)		39 (22.25-54)	50 (42-56.5)		0
CEA (ng/mL)	> 5	163	28	14.66%	0.217
CEA (ng/mL)	≤ 5	118	29	19.73%	0.217
Differentiation	Moderate-poor	274	44	13.84%	0.001
Differentiation	Well	44	20	31.25%	0.001
DTAV (cm)	< 5	140	41	22.65%	0.024
DTAV (cm)	≥ 5	191	31	13.96%	0.024
TL (cm)	> 3	237	41	14.75%	0.001
TL (cm)	≤ 3	73	30	29.13%	0.001
TCE	< 50%	37	7	15.91%	0.772
TCE	≥ 50%	256	55	17.68%	0.772
cT	2	16	5	23.81%	0.405
	3	234	56	19.31%
	4	54	8	12.90%
cN	+	235	57	19.52%	0.465
cN	-	78	15	16.13%	0.465
MRF	-	231	61	20.89%	0.013
MRF	+	97	11	10.19%	0.013
NT regimen	Capecitabine/de Gramont-RT	102	13	11.30%	0
	mFOLFOX6	148	14	8.64%
	mFOLFOX6-RT	81	45	35.71%

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 2 Predictive factors for complete pathological response in multivariate logistic regression analysis for all patients

Variable		P-value	OR	95%CI
Age (yr)	≤ 60	0.703	0.873	0.434-1.756
Age (yr)	> 60		1
Differentiation	Well	0.003	2.966	1.449-6.069
Differentiation	Moderate-poor		1
TL (cm)	≤ 3	0.004	2.608	1.347-5.052
TL (cm)	> 3		1
DTAV	≥ 5	0.07	0.56	0.299-1.049
DTAV	< 5		1
MRF	-	0.017	2.729	1.199-6.211
MRF	+		1
NT regimen	mFOLFOX6-RT	0	5.339	2.394-11.903
	mFOLFOX6	0.402	1.821	0.449-7.387
	Capecitabine/de Gramont-RT		1
The interval		0.093	1.029	0.995-1.064

pCR: Complete pathological response; TL: Tumor length; DTAV: Distance of tumor from the anal verge; NT: Neoadjuvant therapy; MRF: Mesorectal fascia.

Table 3 Predictive factors for good downstaging in univariate logistic regression analysis for all patients

Variable		Bad downstaging (n = 226) n P₅₀ (P₂₅-P₇₅)	Good downstaging (n = 177) n P₅₀ (P₂₅-P₇₅)	Good downstaging rate	P-value
Gender	Male	164	117	41.64%	0.106
Gender	Female	59	60	50.42%	0.106
Age (yr)	≤ 60	144	120	45.45%	0.462
Age (yr)	> 60	80	57	41.61%	0.462
BMI (kg/cm²)	< 25	159	125	44.01%	0.475
BMI (kg/cm²)	≥ 25	56	37	39.78%	0.475
Hemoglobin (g/L)	≤ 125	69	56	44.80%	0.426
Hemoglobin (g/L)	> 125	127	86	40.38%	0.426
NLR	> 3	27	21	43.75%	0.792
NLR	≤ 3	169	121	41.72%	0.792
Platelet (×10⁹/L)		241 (207-294)	236 (193-272.25)		0.125
ApoA1 (g/L)		1.27 (1.13-1.44)	1.31 (1.15-1.48)		0.228
ApoB (g/L)		0.98 (0.79-1.13)	0.97 (0.79-1.18)		0.88
The interval		39 (23-54)	48 (25.75-55)		0.062
CEA (ng/mL)	> 5	125	66	34.55%	0.002
CEA (ng/mL)	≤ 5	71	76	51.70%	0.002
Differentiation	Moderate-poor	194	124	38.99%	0
Differentiation	Well	20	44	68.75%	0
DTAV (cm)	< 5	85	96	53.04%	0.001
DTAV (cm)	≥ 5	141	81	36.49%	0.001
TL (cm)	> 3	167	111	39.93%	0.002
TL (cm)	≤ 3	44	59	57.28%	0.002
TCE	< 50%	23	21	47.73%	0.508
TCE	≥ 50%	179	132	42.44%	0.508
cT	2	4	17	80.95%	0
	3	160	130	44.83%
	4	46	16	25.81%
cN	+	166	126	43.15%	0.074
cN	-	43	50	53.76%	0.074
MRF	-	142	150	51.37%	0
MRF	+	81	27	25.00%	0
NT regimen	Capecitabine/de Gramont-RT	64	51	44.35%	0.061
	mFOLFOX6-RT	61	65	51.59%
	mFOLFOX6	101	61	37.65%

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 4 Predictive factors for good downstaging in multivariate logistic regression analysis for all patients

Variable		P-value	OR	95%CI
CEA (ng/mL)	≤ 5	0.095	1.565	0.925-2.647
CEA (ng/mL)	> 5		1
Differentiation	Well	0	4.814	2.343-9.892
Differentiation	Moderate-poor		1
DTAV (cm)	≥ 5	0.052	0.588	0.345-1.004
DTAV (cm)	< 5		1
TL (cm)	≤ 3	0.9	1.04	0.566-1.909
TL (cm)	> 3		1
cT	3	0.046	0.248	0.063-0.974
	4	0.127	0.282	0.056-1.434
	2		1
MRF	-	0	4.226	1.894-9.426
MRF	+		1

DTAV: Distance of tumor from the anal verge; TL: Tumor length; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 5 Distribution of pretreatment clinical parameters in different neoadjuvant therapy regimen groups

Variable		Capecitabine/deGramont-RT n (%) P₅₀ (P₂₅-P₇₅)	mFOLFOX6 n (%) P₅₀ (P₂₅-P₇₅)	mFOLFOX6-RT n (%) P₅₀ (P₂₅-P₇₅)	P-value
Gender	Male	76 (66.67)	107 (66.88)	98 (77.78)	0.083
Gender	Female	38 (33.33)	53 (33.13)	28 (22.22)
Age (yr)	≤ 60	66 (57.39)	102 (63.75)	96 (76.19)	0.007
Age (yr)	> 60	49 (42.61)	58 (36.25)	30 (23.81)	0.007
BMI (kg/cm²)	< 25	83 (76.85)	118 (76.62)	83 (72.17)	0.641
BMI (kg/cm²)	≥ 25	25 (23.15)	36 (23.38)	32 (27.83)	0.641
Hemoglobin (g/L)	≤ 125	34 (34.34)	55 (39.29)	36 (36.36)	0.729
Hemoglobin (g/L)	> 125	65 (65.66)	85 (60.71)	63 (63.64)	0.729
NLR	> 3	16 (16.16)	17 (12.14)	15 (15.15)	0.646
NLR	≤ 3	83 (83.84)	123 (87.86)	84 (84.85)	0.646
CEA (ng/mL)	> 5	56 (56.57)	79 (56.43)	56 (56.57)	1
CEA (ng/mL)	≤ 5	43 (43.43)	61 (43.57)	43 (43.43)	1
Differentiation	Moderate-poor	90 (81.08)	135 (87.1)	93 (80.17)	0.246
Differentiation	Well	21 (18.92)	20 (12.9)	23 (19.83)	0.246
DTAV (cm)	< 5	61 (53.04)	62 (38.27)	58 (46.03)	0.049
DTAV (cm)	≥ 5	54 (46.96)	100 (61.73)	68 (53.97)	0.049
TL (cm)	> 3	82 (74.55)	105 (70)	91 (75.21)	0.572
TL (cm)	≤ 3	28 (25.45)	45 (30)	30 (24.79)	0.572
TCE	< 50%	10 (10)	22 (15.28)	12 (10.81)	0.389
TCE	≥ 50%	90 (90)	122 (84.72)	99 (89.19)	0.389
cN	+	84 (75)	110 (73.33)	98 (79.67)	0.462
cN	-	28 (25)	40 (26.67)	25 (20.33)	0.462
MRF	-	85 (74.56)	119 (74.38)	88 (69.84)	0.627
MRF	+	29 (25.44)	41 (25.63)	38 (30.16)	0.627
pCR	Non-pCR	102 (88.7)	148 (91.36)	81 (64.29)	0
pCR	pCR	13 (11.3)	14 (8.64)	45 (35.71)	0
Downstaging	Bad	64 (55.65)	101 (62.35)	61 (48.41)	0.061
Downstaging	Good	51 (44.35)	61 (37.65)	65 (51.59)	0.061
cT	2	9 (8.26)	10 (6.85)	2 (1.69)	0.19
	3	85 (77.98)	112 (76.71)	93 (78.81)
	4	15 (13.76)	24 (16.44)	23 (19.49)
PLT (×10⁹/L)		230 (188.75-267.25)	236.5 (200.25-290.75)	244 (212-281)	0.168
ApoA1 (g/L)		1.31 (1.14-1.47)	1.29 (1.12-1.44)	1.28 (1.15-1.5)	0.73
ApoB (g/L)		0.97 (0.8-1.09)	0.98 (0.78-1.14)	0.98 (0.81-1.21)	0.425
The interval		54 (49-58.25)	22 (18-25.75)	52 (47-59)	0

Table 6 Predictive factors for complete pathological response in univariate logistic regression analysis for the capecitabine/deGramont-RT regimen

Variable		Non-pCR (n = 102) n P₅₀ (P₂₅-P₇₅)	pCR (n = 13) n P₅₀ (P₂₅-P₇₅)	pCR rate	P-value
Gender	Male	70	6	7.89%	0.096
Gender	Female	31	7	18.42%	0.096
Age (yr)	≤ 60	56	10	15.15%	0.131
Age (yr)	> 60	46	3	6.12%	0.131
BMI (kg/cm²)	< 25	75	8	9.64%	0.375
BMI (kg/cm²)	≥ 25	21	4	16.00%	0.375
Hemoglobin (g/L)	≤ 125	33	1	2.94%	0.087
Hemoglobin (g/L)	> 125	56	9	13.85%	0.087
NLR	> 3	12	4	25.00%	0.031
NLR	≤ 3	77	6	7.23%	0.031
PLT (×10⁹/L)		228 (188.25-266.75)	252 (188.75-319)		0.338
ApoA1 (g/L)		1.3 (1.14-1.48)	1.34 (1.11-1.46)		0.912
ApoB (g/L)		0.97 (0.8-1.09)	0.92 (0.78-1.02)		0.667
The interval		53.97 ± 8.94	52.38 ± 10.79		0.588
CEA (ng/mL)	> 5	51	5	8.93%	0.659
CEA (ng/mL)	≤ 5	38	5	11.63%	0.659
Differentiation	Moderate-poor	82	8	8.89%	0.177
Differentiation	Well	17	4	19.05%	0.177
DTAV (cm)	< 5	52	9	14.75%	0.214
DTAV (cm)	≥ 5	50	4	7.41%	0.214
TL (cm)	> 3	74	8	9.76%	0.252
TL (cm)	≤ 3	23	5	17.86%	0.252
TCE	≤ 50%	10	0	0.00%	0.241
TCE	> 50%	79	11	12.22%	0.241
cT	2	7	2	22.22%	0.521
	3	75	10	11.76%
	4	14	1	6.67%
cN	+	73	11	13.10%	0.394
cN	-	26	2	7.14%	0.394
MRF	-	74	11	12.94%	0.377
MRF	+	27	2	6.90%	0.377

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 7 Predictive factors for complete pathological response in multivariate logistic regression analysis for the capecitabine/deGramont-RT regimen

Variable		P value	OR	95%CI
NLR	> 3	0.042	4.278	1.051-17.413
NLR	≤ 3		1

NLR: Neutrophil-lymphocyte ratio.

Table 8 Predictive factors for complete pathological response in univariate logistic regression analysis for the mFOLFOX6-RT regimen

Variable		Non-pCR (n = 81) n P₅₀ (P₂₅-P₇₅)	pCR (n = 45) n P₅₀ (P₂₅-P₇₅)	pCR rate	P-value
Gender	Male	63	35	35.71%	1
Gender	Female	18	10	35.71%	1
Age (yr)	≤ 60	62	34	35.42%	0.901
Age (yr)	> 60	19	11	36.67%	0.901
BMI (kg/cm²)	< 25	49	34	40.96%	0.202
BMI (kg/cm²)	≥ 25	23	9	28.13%	0.202
Hemoglobin (g/L)	≤ 125	23	13	36.11%	0.905
Hemoglobin (g/L)	> 125	41	22	34.92%	0.905
NLR	> 3	9	6	40.00%	0.683
NLR	≤ 3	55	29	34.52%	0.683
PLT (×10⁹/L)		246.5 (214.25-289.75)	239 (197-269)		0.22
ApoA1 (g/L)		1.26 (1.15-1.44)	1.3 (1.15-1.55)		0.453
ApoB (g/L)		1 (0.81-1.24)	0.97 (0.81-1.17)		0.725
The interval		51.5 (43-58.75)	54 (50-62)		0.116
CEA (ng/mL)	> 5	40	16	28.57%	0.107
CEA (ng/mL)	≤ 5	24	19	44.19%	0.107
Differentiation	Moderate-poor	63	30	32.26%	0.311
Differentiation	Well	13	10	43.48%	0.311
DTAV (cm)	< 5	33	25	43.10%	0.11
DTAV (cm)	≥ 5	48	20	29.41%	0.11
TL (cm)	> 3	64	27	29.67%	0.008
TL (cm)	≤ 3	13	17	56.67%	0.008
TCE	< 50%	8	4	33.33%	0.944
TCE	≥ 50%	65	34	34.34%	0.944
cT	2	0	2	100.00%	0.061
	3	58	35	37.63%
	4	18	5	21.74%
cN	+	62	36	36.73%	0.946
cN	-	16	9	36.00%	0.946
MRF	-	49	39	44.32%	0.002
MRF	+	32	6	15.79%	0.002

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 9 Predictive factors for complete pathological response in multivariate logistic regression analysis for the mFOLFOX6-RT regimen

Variable		P value	OR	95%CI
TL (cm)	≤ 3	0.046	2.452	1.015-5.926
TL (cm)	> 3		1
MRF	-	0.008	3.829	1.42-10.325
MRF	+		1

TL: Tumor length; MRF: Mesorectal fascia.

Table 10 Predictive factors for complete pathological response in univariate logistic regression analysis for the mFOLFOX6 regimen

Variable		Non-pCR (n = 148) n P₅₀ (P₂₅-P₇₅)	pCR (n = 14) n P₅₀ (P₂₅-P₇₅)	pCR rate	P-value
Gender	Male	99	8	7.48%	0.418
Gender	Female	47	6	11.32%	0.418
Age (yr)	≤ 60	92	10	9.80%	0.532
Age (yr)	> 60	54	4	6.90%	0.532
BMI (kg/cm²)	< 25	107	11	9.32%	0.477
BMI (kg/cm²)	≥ 25	34	2	5.56%	0.477
Hemoglobin (g/L)	≤ 125	53	2	3.64%	0.093
Hemoglobin (g/L)	> 125	75	10	11.76%	0.093
NLR	> 3	16	1	5.88%	0.673
NLR	≤ 3	112	11	8.94%	0.673
PLT (×10⁹/L)		127.5 (117.5-139)	137.5 (127-142.25)		0.82
ApoA1 (g/L)		1.28 (1.11-1.42)	1.3 (1.15-1.46)		0.542
ApoB (g/L)		0.96 (0.77-1.13)	1.13 (0.86-1.3)		0.051
The interval		21.5 (18-25)	25 (19.25-26.75)		0.09
CEA (ng/mL)	> 5	72	7	8.86%	0.889
CEA (ng/mL)	≤ 5	56	5	8.20%	0.889
Differentiation	Moderate-poor	129	6	4.44%	0
Differentiation	Well	14	6	30.00%	0
DTAV (cm)	< 5	55	7	11.29%	0.345
DTAV (cm)	≥ 5	93	7	7.00%	0.345
TL (cm)	> 3	99	6	5.71%	0.02
TL (cm)	≤ 3	37	8	17.78%	0.02
TCE	< 50%	19	3	13.64%	0.413
TCE	≥ 50%	112	10	8.20%	0.413
cT	2	9	1	10.00%	0.974
	3	101	11	9.82%
	4	22	2	8.33%
cN	+	100	10	9.09%	0.866
cN	-	36	4	10.00%	0.866
MRF	-	108	11	9.24%	0.707
MRF	+	38	3	7.32%	0.707

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Table 11 Predictive factors for complete pathological response in multivariate logistic regression analysis for the mFOLFOX6 regimen

Variable		P-value	OR	95%CI
Differentiation	Well	0.002	8.881	2.263-34.85
Differentiation	Moderate-poor		1
TL	≤ 3	0.022	4.805	1.25-18.466
TL	> 3		1

TL: Tumor length.

Citation: Ren DL, Li J, Yu HC, Peng SY, Lin WD, Wang XL, Ghoorun RA, Luo YX. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer. World J Gastroenterol 2019; 25(1): 118-137
URL: https://www.wjgnet.com/1007-9327/full/v25/i1/118.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i1.118